AIM: Pituitary tumor transforming gene (PTTG1) is overexpressed in a variety of tumors, including carcinomas of the lung, breast, colon, as well as in leukemia, lymphoma and pituitary adenomas. However, there is little information on its expression in gastric carcinoma. We sought to investigate the expression of PTTG1 in gastric carcinoma and to explore the relationship between its expression and clinicopathological factors. METHODS: We studied 75 primary human gastric adenocarcinomas, including 17 mucosal carcinomas, 21 submucosal infiltrative carcinomas, 12 carcinomas invading proprial muscle layers, 6 carcinomas reaching the subserosa, and 19 carcinomas penetrating the serosal surface. Immunohistochemical analysis was performed using paraffin-embedded sections of gastric adenocarcinomas. RESULTS: PTTG1 was expressed heterogeneously in carcinomas. Positive PTTG1 staining was observed in 65.3% of the carcinomas (49 of 75). Its expression did not correlate significantly with either the histological type or the depth of infiltration of the gastric carcinomas. However, a statistical analysis showed significant differences between the primary adenocarcinomas and the associated metastatic lymph nodes. CONCLUSION: The results of this study demonstrate that PTTG1 expression is enhanced in metastatic lymph nodes in comparison to that in primary carcinomas. We suggest that PTTG1 may contribute to lymph node metastases in gastric carcinoma.
AIM: Pituitary tumor transforming gene (PTTG1) is overexpressed in a variety of tumors, including carcinomas of the lung, breast, colon, as well as in leukemia, lymphoma and pituitary adenomas. However, there is little information on its expression in gastric carcinoma. We sought to investigate the expression of PTTG1 in gastric carcinoma and to explore the relationship between its expression and clinicopathological factors. METHODS: We studied 75 primary humangastric adenocarcinomas, including 17 mucosal carcinomas, 21 submucosal infiltrative carcinomas, 12 carcinomas invading proprial muscle layers, 6 carcinomas reaching the subserosa, and 19 carcinomas penetrating the serosal surface. Immunohistochemical analysis was performed using paraffin-embedded sections of gastric adenocarcinomas. RESULTS:PTTG1 was expressed heterogeneously in carcinomas. Positive PTTG1 staining was observed in 65.3% of the carcinomas (49 of 75). Its expression did not correlate significantly with either the histological type or the depth of infiltration of the gastric carcinomas. However, a statistical analysis showed significant differences between the primary adenocarcinomas and the associated metastatic lymph nodes. CONCLUSION: The results of this study demonstrate that PTTG1 expression is enhanced in metastatic lymph nodes in comparison to that in primary carcinomas. We suggest that PTTG1 may contribute to lymph node metastases in gastric carcinoma.
Authors: C Sáez; M A Japón; F Ramos-Morales; F Romero; D I Segura; M Tortolero; J A Pintor-Toro Journal: Oncogene Date: 1999-09-23 Impact factor: 9.867
Authors: A Domínguez; F Ramos-Morales; F Romero; R M Rios; F Dreyfus; M Tortolero; J A Pintor-Toro Journal: Oncogene Date: 1998-10-29 Impact factor: 9.867
Authors: N Gurvits; H Repo; E Löyttyniemi; M Nykänen; J Anttinen; T Kuopio; K Talvinen; P Kronqvist Journal: Cell Oncol (Dordr) Date: 2016-03-16 Impact factor: 6.730
Authors: Tetsuo Ito; Yutaka Shimada; Takatsugu Kan; Stefan David; Yulan Cheng; Yuriko Mori; Rachana Agarwal; Bogdan Paun; Zhe Jin; Alexandru Olaru; James P Hamilton; Jian Yang; John M Abraham; Stephen J Meltzer; Fumiaki Sato Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: K Talvinen; H Karra; S Hurme; M Nykänen; A Nieminen; J Anttinen; T Kuopio; P Kronqvist Journal: Br J Cancer Date: 2009-08-18 Impact factor: 7.640